Cardiovascular

Year Description
2002 [Germany] 1st safety report of Autologous mononuclear BMCs의 selective intracoronary transplantation by Dr. Strauer
2002 [Germany] TOPCARE-AMI (Non-randomized trial)
2002 [Spain] Dr. Francisco Fernandez-Aviles, Jose (Non-randomized trial)
2005 [USA] the first postmortem findings was reported
2006 [Germany] first trial (TOPCARE-CHDI) for CMI patients was reported
2006 [Germany] BOOST trial (Randomized controlled trial) ? 60 subjects
2006 [Germany] REPAIR-AMI trial (Randomized double blind placebo controlled trial) Multicenter trial-204 patients were enrolled
2006 [Belgium] Janssens’ study (Negative results)
2006 [Norway] Lunde’s study (Negative results)
2006 [Germany] 18-mo follow-up study of BOOST trial (Negative results)
2008 4 Meta-analysis were reported
2009 [Germany] Reported 60-mo long-term follow-up study (BALANCE study)
2009 [USA] the first 'off the shelf' MSC (Prochymal) study results was reported
2009 [Germany] 5-year follow-up study (Balance stidy) was reported
2011 [USA] Phase I study of injection of cardiac stem cell (SCIPIO) was reported
2012 [JAPAN] a hybrid cell therapy application (cardiac stem cells together with basic Fibroblast Growth Factor (bFGF) study was reported
2012 [USA] autologous cardiac-derived cells were applied in patients who developed LV dysfunction
2012 Optimization studies were reported, such as superior cell population, timing, dosing, delivery mode
2015 [USA] Negative results of individual patients data from 12 randomized trials of AMI was reported
2015 [USA] Transendocardial injections of allogeneic MPCs' feasiblity study was reported
Year Description
2001 The first application of Myoblast in human
2004 Tried various administration of route
-CABG/ LVAD/ surgery
-Evidence of safety using NOGA system (3 articles)
-Off-pump surgery methods used in cell injection(2 articles)
2005 Reported 3 Randomized controlled studies
-[USA] The first report of prospective RCT
-[Germany] 2 RCTs
2007 Long-term safety and efficacy studies were reported (6 articles)
2011 Combination cell injection or cell injection with other treatment methods
-BMC+Myoblast
-BMC+MSC
-BMC+CRT
2012 Randomized controlled studies were reported using novel cell
-1st report applied CDC
-1st RCT using ALDH cell
Year Description
Year Description
2006 4 clinical trials were reported in patients with Dilated CMP
-PBSC intramyocardial injection by thoracotomy
-[India] ABCD trial (RCT)
2008 [USA] 1st safety and efficacy report MSC injection
2008 [Russia] IC injection of MSC
2008 [Malaysia] Cryopreservation protocol for the MSC
2010 [India] Reported 3-year follow-up results of ABCD trial
2011 [Slovenia] IC injection of PBSC (CD34 cell) ? survival analysis
-1-year FU(2011)
-5-year FU(2013)
2011 [UK] REGENERATE-DCM protocol ? placebo controlled study
2012 [Japan] Tissue engineered Myoblast sheet
Year Description
Year Description

Bone

Year Description
1996 [Belgium] Report of intralesional implantation of a bone paste made of autogeneic bone marrow and allogeneic bone powder into aneurysmal bone cyst
1996 [Israel] Report of percutaneous autologous marrow grafting alone for the
treatment of simple bone cysts
1998 [Belgium] Demonstration of feasibility of a single percutaneous aspiration and injection of marrow into simple bone cyst
2000 [Japan] Report autologous bone marrow grafting was useful method for the treatment of non-ossifying fibroma
2002 [USA] Reporting In 79 consecutive patients with unicameral bone
Cysts treated injection of bone marrow (Negative study)
2003 [Belgium] Demonstration safety and efficacy of a single percutaneous injection of bone marrow into simple bone cyst at risk for fracture
2004 [Germany] 1st report of the use of adipose derived stem cells to augment cancellous bone (calvarial defect)
2007 [Korea] A comparison of injection of steroid and grafting with autologous bone marrow for treatment of simple bone cysts
2007 [Italy] Using porous hydroxyapatite (HA)
ceramic scaffolds with demineralized bone matrix and autologous bone marrow to for treatment of large bone diaphysis defects
2008 [Greece] Report the benefit of the elastic intramedullary nailing with demineralized bone matrix and iliac crest bone marrow injection
2008 [Korea] Reporting Open Chip Allogeneic
Bone Graft versus Percutaneous Injection of Bone Powder with Autogenous
Bone Marrow for treatment of Calcaneus bone cyst
2008 [Italy] Histological and immunohistochemical analysis of large segmental defect of the ulna treated with an allogenic bone
Graft with autologous bone marrow mononuclear cells
2008 The Simple Bone Cyst Trial Group study (multicenter, randomized clinical trial)
2010 [Italy] Report A single injection of DBM added with
autologous bone marrow concentrate into Unicameral Bone Cyst
2011 [Germany] Using bone marrow aspiration concentrate for treatment of local bone defects with a defect area
2011 [Greece] Report Autologous Bone Marrow Grafting Combined with
Demineralized Bone Matrix into tibial bone defect
2013 [USA] Timothy’s study (Negative study)
2013 [France] Reporting cancer risk is not increased in patients treated for orthopaedic disease with autologous bone marrow cell
Year Description
1989 [USA] Reporting of autologous bone marrow Injection into non-union of tibia
1993 [UK] Percutaneous injection of autologous bone marrow into non-union (20case)
1993 [Singapore] Percutaneous injection of autologous bone marrow into non-union (10case)
2004 [Nepal] Treatment of non-union of tibia using autologous bone marrow injection (randomized study)
2005 [UK] Demonstration safety and reliability of bone marrow injection for non-union of tibia
2006 [Japan] Report Treatment with BMNC implantation for intractable tibia fracture followed by compartment syndrome
2007 [UK] Treatment of non-union of tibia using Calcium sulphate with ABM
2009 [Germany] Using cancellous allograft vitalised
with autologous bone marrow for fibula and tibia fusion
2009 [Taiwan] Using autologous bone marrow treatment for Clavicular non-union associated with thoracic outlet syndrome
2009 [Korea] Demonstration of safety of autologous cultured osteoblast injection to long-bone fracture (multicenter, randomization trial)
2010 [USA] 1st described case of augmenting sternal stabilization with osteoprogenitor cell?impregnated allogeneic bone matrix
2011 [Italy] Demonstration of effect of lyophilized bone, platelet gel (PG) and BMSCs in shortening the healing time in fracture non-union.
2012 [Italy] Using platelet gel and bone marrow stromal cells for post-traumatic femoral non-union
2013 [USA] Reporting Percutaneous Autologous Bone Marrow Injection into Distal Meta-diaphyseal tibial uonunions and delayed unions
2013 [Italy] Reporting long term healing of non-union(76 months) of MSCs injection in Upper limb non-union
2013 [USA] Reporting multiple injections of low-volume bone
Marrow for delayed or non-union of bones
2013 [USA] Using MSCs for foot and ankle arthrodesis
2014 [Japan] 1st clinical trial of transplantation of autologous, G-CSF-mobilized and purified
CD34+ cells in patients with tibial or femoral nonunion
2014 [Italy] Demonstration of feasibility using Opposite Structural Allograft, BMP-7,
and Mesenchymal Stem Cells for eldery patient with Humeral Shaft Aseptic
Nonunions
Year Description
2006 [Switzerland] Report of Instrumented fusion of thoracolumbar fracture with type I
mineralized collagen matrix combined with autogenous bone marrow
2007 [USA] Demonstration of safety and effectiveness of collagen-hydroxyapatitie matrix with BMA in anterior cervical fusion
2007 [Spain] Demonstration of ability to generate sufficient bone mass of BMA mixed BCP ceramic
2009 [USA] 1st study to evaluate BMA/CHS grafts through and around interbody cages in
TLIF and posterolateral gutters in PLF.
2009 [UK] Report of macroscopic and histologic appearance of bone after implantation of BMA with Healos
2013 [Austria] Report of beta-tricalcium phosphate and BMA as a bone graft substitute in posterior lumbar interbody fusion (Negative study)
Year Description
1997 [France] Reporting on the allograft BMT in Osteonecrosis by Sickle-cell anemia
2002 [France] 1st report to describe autologous bone marrow transplantation in ONFH
2004 [Belgium] Study using autologous bone marrow transplantation in ONFH (controlled, double blinded study)
2006 [Japan] Using autologous MSC in Steroid-induced ONFH
2008 [Turkey] Demonstration of efficacy in ARCO stage I-II ONFH
2010 [Japan, China] 2 studies reported using BMMNCs
2011 [Belgium] Reporting 5 yr long-term follow up study of autologous bone marrow cell implantation
2012 [China] Implantation of ex vivo expanded BMMSCs (randomized study)
2012 [Korea] 1st report of treated with adipose tissue-derived stem cells for ONFH
2013 [Korea] Reporting minimum 5yr follow up study
2013 [Korea] Lim’s study (Negative study)
2013 [China] Demonstration safety and feasibility of intra-arterial delivery of BMMNCs
Year Description
2006 [USA] Report of intradiscal injection of hematopoietic stem cells in patient with back pain (negative study)
2010 [Japan] Disc Regeneration therapy using bone marrow MSC transplantation in spinal stenosis
2011 [Spain] Demonstration of safety and feasibility of using autologous MSC in lumbar disc degeneration
Year Description
1995 [UK] 1st report of percutaneous autologous bone marrow grafting in congenital tibial pseudoarthrosis
2004 [Japan] Report of Clinical results of distraction osteogenesis with transplantation of MSCs and PRP
2007 [Japan] Demonstration of Transplantation of BMC and PRP shortened the treatment period by accelerating new bone regeneration
2009 [Japan] Report favorable effects of new bone generation
2010 [Finland] Report of MSC transplantation in congenital pseudarthrosis of the tibia (CPT) caused by neurofibromatosis type 1 (NF1)
2012 [Italy] Report of MSC transplantation in congenital pseudarthrosis of the tibia (CPT) caused by NF1 (2 article)
2012 [Italy] Report of pseudoarthrosis of the upper limb using expanded MSC
2013 [Spain] Demonstration of safety and feasibility of combination therapy of autologous BM-MNCs and allogenic bone graft
Year Description
2007 [USA] Using bone block allograft impregnated with
bone marrow aspirate demonstrated easy and safe
2008 [Russia] Using adipose tissue derived MSC in maxillary and mandibulary bone deficit reported
2009 [Italy] Using dental pulp stem cell with collagen sponge biocomplexes reported
2010 [Brazil] Evaluation of extraction sockets treated with an autologous bone marrow graft (randomized trial)
2011 [Japan] Finding that particulate cellular bone and marrow and platelet-rich plasma ?reconstructed mandibles resembled normal mandibles
2012 [Spain] Reporting the mesh was filled with two blocks of xenogenic material mixed with recombinant bone morphogenetic protein 7 (BMP-7) and autologous MSC
2013 [Korea] 1st report of a successful reconstruction performed
for treating a mandibular defect by using autologous human
bone marrow mesenchymal stem cells in a patient with plexiform
ameloblastoma
2013 [Finland] 1st reprot of a mixed population of autologous cultured bone marrow?
derived stem and progenitor cells in the treatment
of mandibular defect
Year Description
2011 [Italy] 2 year follow up using MRI T2-mapping sequence in osteochondral lesions of ankle with BM transplantation
2012 [Singapore] Reporting of autologous chondrocyte implantation and cultured bone marrow stem cell implantation in Patellar Osteochondritis Dissecans
Year Description
2002 [Japan] Report of autologous cultured expanded BM-MSC transplantation for repair of cartilage defects in OA knee
2004 [Japan] Using autologous MSC in full-thickness articular cartilage defects
2005 [Japan] Report a large osteochondral defect of the knee after septic arthritis treated by BMMSC and IP-CHA
2006 [Poland] Demonstration of a correlation between defect size and result in cartilage defect of the knee treated by autologous bone marrow
2007 [Japan] Reporting of autologous BMSC treatment in young and active patient
2009 [Italy] Treat Osteochondral lesions of the talus using bone marrow derived cell transplantation
2010 [Italy] Report a open field autologous chondrocyte implantation in post-traumatic osteochondral lesions of the talus
2011 [USA] intraarticular injections of autologous
peripheral blood progenitor cells in combination with hyaluronic acid into chondral injury of knee
2012 [Singapore] Demonstration of safety of arthroscopic microfracture and Injections of MSCs and hyaluronic acid for cartilage repair in the human knee
2013 [Italy] Reporting 3 year follow up study of bone marrow derived cell transplantation
2013 [Italy] Reporting 4 year follow up study of bone marrow derived cell transplantation in Talar Osteochondral Lesions
2013 [Korea] Reporting clinical outcomes of MSC Injection in older patients(>50yr) with
osteochondral lesions of the talus
2013 [USA] Saw’s study (randomized controlled trial)
2013 [Singapore] Transplantation of Injectable BMMSC in varus knees with cartilage Defects undergoing HTO (Prospective, Randomized Controlled Clinical Trial With 2 Years’ Follow-up)
2014 [Korea] Using Adipose-derived MSC in Osteochondral Lesions of the Talus
2014 [USA] 1st controlled data on the results of injecting allogeneic mesenchymal stem
cells into the knee in humans and supports the safety of intraarticular
injection of human mesenchymal stem cells (A randomized, double-blind, controlled study)
Year Description
2010 [Spain] 1st report the first use of a autologous cultured bone marrow? derived stem in the treatment of severe craniofacial disorders
2011 [Italy] 1st case of BRONJ successfully treated with autologous stem cells
transplantation with a complete response
2013 [Japan] Reporting of using autologous bone marrow in the treatment of Kienbo¨ck’s disease
Year Description
2006 [Switzerland] Report of Instrumented fusion of thoracolumbar fracture with type I
mineralized collagen matrix combined with autogenous bone marrow
2007 [USA] Demonstration of safety and effectiveness of collagen-hydroxyapatitie matrix with BMA in anterior cervical fusion
2007 [Spain] Demonstration of ability to generate sufficient bone mass of BMA mixed BCP ceramic
2009 [USA] 1st study to evaluate BMA/CHS grafts through and around interbody cages in
TLIF and posterolateral gutters in PLF.
2009 [UK] Report of macroscopic and histologic appearance of bone after implantation of BMA with Healos
2013 [Austria] Report of beta-tricalcium phosphate and BMA as a bone graft substitute in posterior lumbar interbody fusion (Negative study)
Year Description
2006 [Italy] Report of Osteogenesis induced by autologous bone
marrow cells transplant in the pediatric skull defect
Year Description
2008 [Japan] Report of injectable tissue-engineered bone with BMDSCs for Maxillary Sinus Augmentation
2009 [Italy] Report of culture of autogenous osteoblasts seeded on polyglycolic?polylactic scaffolds and calcium phosphate for Maxillary Sinus Augmentation
Year Description
1977 [France] Report of BMT for infant osteopestrosis
1981 [USA] Report of BMT from HLA identical silbling for The juvenile form of osteopetrosis
1986 [France] European surgery: BMT for immunodeficiency and osteopetrosis
1991 [UK] Report of hypercalcaemia after BMT for osteopetrosis
1994 The Working Party on Congenital Diseases of the European Group
for BMT’s study
1996 [Switzerland] Report of BMT for cartilage-hair hypoplasia
1996 [Canada] Demonstration of changing of phenotype in osteopestrosis
1997 [Italy] Demonstration of feasibility of cord blood transplantation in osteopestrosis
1999 [USA] Demonstration of feasibility of allogenic BMMSC in osteogenesis imperfecta
1999 [USA] BMT for osteogenesis imperfecta
2000 [Italy] Report 5 and 6-year long term follow up of BMT for osteopestrosis
2000 [USA] Report of Reversal of Optic Canal Stenosis in osteogenesis imperfect by BMT
2001 [UK] Report of treatment osteopetrosis in the carbonic anhydrase II
deficiency syndrome by BMT
2002 [USA] Demonstration of feasibility of Isolated allogeneic bone marrow-derived
mesenchymal cells for treatment of osteogenesis imperfecta
2002 [Sweden] Report dental development after successful treatment of infantile
osteopetrosis with bone marrow transplantation
2002 [Germany] Report of Patients
with OP lacking HLA-matched donors treated by purified blood progenitor cells
2003 the Working Party on Inborn Errors of the European Group
for Blood and Marrow Transplantation (EBMT) study: HSCT for osteopestrosis
2004 the
Working Party on Inborn Errors of the European Group
for Blood and Marrow Transplantation (EBMT) study: complication report
2005 [Sweden] Report of fetal mesenchymal stem-cell engraftment in bone
after In utero transplantation in a patient with severe
osteogenesis imperfecta
2006 [Taiwan] Report of unrelated mismatched cord blood transplantation for infantile osteopetrosis
2007 [USA] Report Infantile Hypophosphatasia treated by BMT
2009 [Japan] Report Allogeneic Mesenchymal Stem Cell
Transplantation in Perinatal Hypophosphatasia
2012 [Russia] 1st report of autologous hematopoietic SCT for ankylosing spondylitis
2013 [USA] Demonstration of safety of cord blood transplantation for malignant infantile osteopetrosis and hemophilia
2014 [UK] Report of human fetal chorionic stem cell transplantation for Osteogenesis Imperfecta
Year Description
Year Description
Year Description
Year Description
Year Description

Neurology

Year Description
2005 [USA] 1st report on the transplantation of Fetal Porcine Cells in ischemic stroke patients
2005 [Korea] 1st report to describe Autologous MSC Transplantation in Stroke Patients
2006 [Poland] 1st demonstration of mobilization of human hematopoietic stem/progenitor-enriched CD34+ cells into peripheral blood
2007 [Brazil] Testing feasibility of monitoring ABMMN cells implanted into the brain by the technique of labeling with Tc- 99m-HMPAO
2007 [USA] Though 10% DMSO is a standard carrier for stem cells, alternative agents or a lesser concentration of DMSO may be safer and equally effective.
2009 [Cuba] Demonstration of safety and feasibility using stereotactic surgery for the first time
2010 [Korea] Reporting 5-year long-term follow-up study of intravenous autologous MSC Transplantation
2010 [Brazil] Observed cell migration and homing using superparamagnetic iron oxides (SPIO) method
2011 [USA] 1st IV injection of ABMMNC for Ischemic Stroke
2011 Report ASSIST: an open-label, randomised phase 2 trial
2012 [Brazil] Demonstration of Intra-Arterial Infusion of Autologous Bone Marrow Mononuclear Cell
2013 Human Adipose-Derived Stromal Cells for Cell-Based Therapies in the Treatment of Systemic Sclerosis
2014 ASTIS Phase II results reported
Year Description
2005 [Russia] Applying cell transplantation therapy in severely head-injured patients as early as within acute period of a disease.
2006 [Russia] Cell technologies can be effectively used for the treatment of patients with Comatose States
2006 [Russia] Finding that immunological privileges of the CNS are not absolute. High reactivity to donor antigens detected in the migration test
2008 [China] A combined procedure to deliver autologous MSC to patients with traumatic brain injury.
2011 [USA] Autologous BMMNC Therapy for Severe Traumatic Brain Injury is safe
Year Description
1997 [Sweden] 1st use of solid human embryonic spinal cord grafts
2005 [Portugal] Pilot clinical study shows that autografts of olfactory mucosa are fairly safe and feasible.
2005 [Australia] Transplantation of autologous olfactory ensheathing cells into the injured spinal cord is feasible and is safe
2006 [Brazil] 1st case that Lumbar Puncture technique in patients with Spinal cord injury.
2006 [China] The first clinical study demonstrating the long-term safety of the OEC therapy for SCI (38-mo f/u study)
2007 [Brazil] For the first time that autologous bone marrow CD34 cells labeled with magnetic nano-particles delivered into the spinal cord.
2008 [USA] BMSCs administration via multiple routes is feasible, safe
2008 [Iran] Autologous Schwann cell transplantation is generally safe
2009 [India] Reported studies to demonstrate impact of cell dose, timing of stem cell transplantation, patients age etc for treatment of stem cell.
2010 [USA] FDA approved GENOPC1 cells (Geron trial)
2012 [Korea] Reported in long-term results of Spinal Cord Injury using MSC.
2012 [China] Fetal Olfactory Ensheathing Glia Transplantation (OEGT) in patients with complete chronic SCI
Year Description
2010 [China] Reported RCT of intracranial transplant of Olfactory Ensheathing Cells in children and adolescents
2012 [Korea] Safety and feasibility of autologous cord blood by intravenous administration
2012 [India] The administration of ABMNC intrathecally and intramuscularly is safe and feasible
2012 [China] NPC transplantation is a safe and effective therapeutic method
Year Description
2007 [USA] Autologous BMMNC Therapy for Severe Traumatic Brain Injury is safe
2009 [China] Application of allogeneic MSC transplantation in MS
2010 [Israel] Safety and immunological effects of MSC transplantation in MS
2010 [Lebanon] Safety and feasibility of MSC with cerebrospinal fluid injection
2010 [UK] Safety and Feasibility of ABMNC with IV administration
2012 [UK] Reported an open-label phase 2a proof-of-concept study of autologous MSC for the treatment of secondary progressive multiple sclerosis
Year Description
2003 [Italy#245] 1st finding safety of autologous MSCs were transplanted in to the spinal cord of 7 ALS patients. It was safe and well tolerated by ALS patients
2006 [Italy#193] Autologous MSCs were intraspinal injected for 7 ALS patients and followed-up for 36 months.
2007 [USA#155] An observational study on a 70-year-old ALS patient who underwent OEC into each frontal lobe in China. Her ALS progressed a more rapid rate after procedure and she suffered from SAE.
2007 [China#A7] Short-term outcome was reported bilaterally corona radiata transplanted of OEC 327 ALS patients.
2007 [China#A8] OEC transplanted for 7 ALS patients and followed up for 2 months.
2008 [China#131] 1st clinical control study regarding the use of OEC transplant through bilateral corona radiata in 35 patients with ALS. (15 OEC VS. 20 not received)
2009 [Turkey#123] BMC were injected 13 ALS patients (bulbar involved and severe loss of movement) within intraspinal (brain stem and beginning of the spinal cord)
2009 [Mexico#115] Autologous CD133 cells were transplanted into the frontal motor cortex for10 ALS patients.
2009 [Italy] Safety report of MSC injection during 4 years
2009 [USA] FDA approved first clinical trial of HSSC injection into the spinal cord for ALS.
2009 [Spain] Finding CD133+ progenitor cells on survival in ALS.
2010 [Italy #91] Pathology of 2 ALS patients who underwent OEC. Undifferenciated cell within delivery track were found. Prominent glial and inflammatory reaction. There was no beneficial effect on fetal OEC implantation.
2010 [The Netherlands#78] An observational study for 7patients who underwent OEC in China. 2 patients were reported SAE (DVT, respiratory insufficiency)
2010 [Spain#70] An observational study of average 47.2 mos for 12 ALS (3 were injected OEC, 9 were MSC). 7 needed ventilation and 5 gastronomy feeding.
2010 [Spain#69] BMSs were inplanted within intrasponal for 11 ALS patients using technical surgical instrument.
2010 [Italy#101] Autologous MSCs were injected through intraspinal for 10 ALS patients after 9-mo observational periods. 14 month followed up to confirm safety.
2010 [Isreal#57] Phase I/II open label study. Autologous MSC was injected for 15 MS and 19 ALS through intrathecally or IV. This study is 1st finding of systemic immunomodulatory effect in ALS patients
2011 [Germany#39] 1st case (a 63-year-old man) of intramedullary thoracic spinal cord implantation of umbilical cord-derived CD34+.
2012 [Italy#A2] Autologous MSCs were injected19 ALS patients through intraspinal and followed up for 9 years to confirm lack of tumor formation or abnormal cell growth. This is the first study to show the safety of MSC in the CNS.
2012 [Korea#A1] A 63-year-old ALS patient was injected autologous MSC through Ommaya reservoir. It is new and safe route. (Hanyang Univ.)
2012 [USA#25] 8 week fetal-derived neural stem cells were injected for 12 ALS patients intraspinal. (Emory University)
2012 [Spain#24] Open single arm phase 1 trial. 10 Autologous BMNC were injected to intraspinal for 11 ALS patients. 6 mos monitor was conducted to see their progression.
2012 [Argentina#17] 7 ALS patients with T-cell vaccination + BEN protocol were able to slow or stop disease progression.
2012 [USA#2] 1st US Food and Drug Administration-authorized phase I trial was reported. (Emory University) Among 12 ALS patients (out of 18) (6 non-ambulatory, 6 ambulatory), dose escalation study
2012 [India#1] in 2009-2010, 10 over 18 ALS patients were enrolled. Autologous BMC injected through intrathecally. 3, 6, 9, 12 mo followed-up using ALSFRS-r for efficacy and median survival and AE were assessed for safety outcome.
Year Description
1985 [Sweden] Reported the first clinical trials of transplantation of adrenal meduallery tissue
1988 [Mexico] 1st published report of fetal nigral grafts in patients with Parkinson’s disease
1990 [Sweden] Evidence of nigral graft survival and functional recovery in patients with Parkinson’s disease
1990 [USA] Found that the blood brain brain barrier was intact using MRI
1994 [Sweden] Grafted embryonic dopamine neurons can survive, grow, and exert functional effects up to at least 3 years
1995 [USA] 1st post-mortem evidence of nigral graft survival in patients with Parkinson’s disease (Kordower)
1997 [USA] 1st report of surviving nigral xenografts in a patient with Parkinson’s disease
1998 [USA] 1st evidence we know of in humans for rewiring of transplanted fetal tissue with host tissue.
1999 [USA] Positron-emission tomography (PET) evidence of regulated dopamine release from nigral grafts in a patient with Parkinson’s disease
2000 [USA] 1st implantation of xenogeneic neural tissue into humans
2001 [USA] 1st reported results of randomized placebo controlled study funded by NIH (Freeman)
2003 [USA] Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on dyskinesia
2006 [Germany] 1st evidence that SPECT and DAT radioligands can be used to monitor the survival and function of intrastriatal dopaminergic grafts in PD patients.
2008 [USA] 1st finding Lewy body?like structures develop in implanted neurons as a result of an
accelerated Parkinson’s disease
Year Description
Year Description
1995 [Mexico] 1st case report of stem cell therapy for HD in English
1997 [USA] 1st report about safety and efficacy in patients with HD
2000 [USA] A postmortem research was reported for the first time
2000 [USA] Use of implanted fetal striatal tissue as a possible treatment for HD.
2002 [UK] NEST-UK safety report
2006 [France] 1st report 6-year long-term follow-up results
2007 [USA] 1st examination of fetal neural transplants in patients with HD several years after surgery.
2008 [Italy] Two separate routes for caudate and putaminal trajectories allowed us to achieve a larger amount of fetal tissue deposits and a better spatial distribution of grafts
2009 [Germany] 1st description of a human brain receiving whole GE-derived implants into the striatum and the earliest time point a human brain with implanted fetal tissue
2010 [Italy] 1st evidence in humans that neuroblasts of a striatal primordium can develop and move into the brain after neuro-transplantation.
Year Description

Autoimmune

Year Description
2004 [Phase I] a 9-year-old boy with severe treatment resistant acute
2008 GVHD third party haploidentical mother-derived MSCs
2009 Prochymal dose finding: Randomized to receive 2 treatments of human MSCs (Prochymal ) at a dose of either 2 or 8 million
2010 [Pilot study] intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease
2010 [case report in Korea] Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease
2011 [Phase II] Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease
Year Description
Year Description
1998 First case report, with long-term follow-up, which suggests that Crohn’s disease could be controlled by ABMT.
2003 The result according to the FDA approved protocol
2005 MRC should be considered an evolving technology that has yet to reveal its full potential in IBD
2007 First large single center analysis of stem cell mobilization in patients with immunemediated diseases
2008 For the first time, that clinical benefits can be reached with a protocol not using CD34+ cell selection.
2010 BM-MSC administration produced clinical benefits in severe refractory Crohn’s disease
2011 For the first time the clinical and endoscopic efficacy of a protocol of autotransplantation which used unselected stem cells.
2013 Allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial
2014 Treatment-free remissions, where achieved, appear to be short in patients with long duration of severe and complex CD
Year Description
1997 First case report of hematopoietic Stem-Cell Transplantation for Systemic Lupus Erythematosus
2001 Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study
2003 Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus
2009 Mesenchymal Stem Cell Transplantation in Systemic Lupus Erythematosus
2010 phase I trial of MSC injection in 15 patients with refractory disease
2014 Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study
Year Description
Year Description
Year Description
1997 First case report published to treat with AHSCT
2001 Phase I/II trial of autologous stem cell transplantation in systemic sclerosis
2003 Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre trial
2004 Nonmyeloablative conditioning may accomplish the same goal with less toxicity and thus may be more desirable
2005 First case report of scleroderma renal crisis (SRC) complicating an HSCT procedure
2007 This study describes for the first time the development of a secondary autoimmune complication among patients undergoing auto-HSCT for an autoimmune condition
2007 the first histopathological analysis was performed in this study
2008 Both with autologous and haploidentical third party donor MSCs has been reported
Year Description
Year Description
Year Description
Year Description
Year Description

Gastrointestinal

Year Description
1998 First report was published of Course of Crohn’s Disease After Allogeneic Marrow Transplantation in USA
2003 Complete remission of Crohn’s disease after autologous stem cell transplantation was reported in Germany
2009 Phase II Clinical Trial of Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula was reported in Spain
2010 phase I study of Autologous bone marrow-derived mesenchymal stromal cell treatment results were published in the Netherlands
2012 phase III Autologous expanded adipose-derived stem cells for the treatment of complex fistula was reported in Spain
2013 Phase I Clinical Study of Autologous Adipose Tissue-Derived Stem Cells for the Treatment of Crohn’s Fistula was published in Korea
2015 Long-Term Results of Adipose-Derived Stem Cell Therapy for the Treatment of Crohn’s Fistula was reported in Korea
2016 Phase III allogeneic MSC treatment effect study was published in Spain
Year Description
1992 Intrahepatic Human Islet Transplantation for 25 patients was reported in USA
2007 Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus in Brazil
2008 Human Adipose Tissue-Derived MSC+Hematopoietic Stem Cell Transplantation results was reported in India
2009 Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells in Brazil
2010 Adipose Tissue-Derived MSC were applied for T1DM
2010 Regeneration of insulin production by autologous bone marrow blood autotransplantation in patients with type 1 diabetes
2012 5 studies on Hematopoietic Stem Cell Transplantation for type 1 DM were published in China
2013 Long term effects of Wharton’s jelly-derived MSC for newly-onset type 1 DM was published in China
2014 Multicenter Analysis of Autologous Hematopoietic Stem Cell Transplantation in New-Onset Type 1 DM was published
2015 Preserved b-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells results was reported in Sweden
2015 Novel therapy for insulin-dependent diabetes mellitus (infusion of in vitro-generated insulin-secreting cells) was introduced in India
Year Description
1997 Donor Bone Marrow Infusions in Conjunction With Liver-Islet Allotransplantation in Patients with Type 2 Diabetes in USA
2005 Locally Applied Mononuclear BM-MNC in a Type 2 Diabetic Patient in Germany
2008 Combined Treatment of Intrapancreatic Autologous Bone Marrow Stem Cells and Hyperbaric Oxygen in Type 2 DM in Argentina
2009 Efficacy study of Autologous BM-MNC in Patients With Type 2 DM was reported in India
2012 Long term effects of the implantation of autologous BM-MNC for type 2 DM was reported in China
2012 A pilot study was reported in transplantation of placenta-derived mesenchymal stem cells in type 2 DM in China
2014 A Randomized Placebo-Controlled Study was published in efficacy and Safety of Autologous BM-MNC in Patients With Type 2 DM in India
2014 A preliminary evaluation was published in efficacy and safety of Wharton’s jelly MSC in patients with type 2 DM in China
2014 An open-label, randomized controlled clinical trial was published in autologous BM-MNC therapy in type 2 DM in China
2015 Biodistribution of 18F-FDG-Labeled Autologous BM-MNC in Patients With Type 2 DM was reported in India
Year Description
2009 A phase I/II clinical trial was reported in patients with liver cirrhosis after autologous MSC in Sweden
2010 Human Fetal Liver-Derived Stem Cell Transplanted in patients of End-Stage Decompensated Liver Cirrhosis in India
2010 A pilot randomized controlled study of autologous BM-MNC infusion in patients with chronic liver disease was published in Austria
2011 Short-Term and Long-Term Outcomes was reported in autologous BM-MSC in China
2011 Phase I study of BM-MNC was published in Brazil
2011 Biodistribution study of MSC infusion in patients with advanced cirrhosis was reported in Iran
2011 Effect of intravenous Autologous BM-MNC Infusion in Patients with Alcoholic Liver Cirrhosis was reported in Japan
2012 Phase II Trial: Undifferentiated Versus Differentiated Autologous Mesenchymal Stem Cells Transplantation in Egyptian Patients with HCV Induced Liver Cirrhosis
2013 A pilot study of autologous CD34-depleted BM-MNC transplantation via the hepatic artery in five patients with liver failure in Korea
2013 Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis was reported in Iran
2013 A Randomized Controlled Trial was reported in results of autologous BM-MNC Transplantation in Patients with Decompensated Alcoholic Liver Disease in Swiss
2013 A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis in China
2014 Randomized trial was reported the results of autologousBM-MSC transplantation for hepatitis B virus cirrhosis in China
2014 A pilot study of histological improvement following administration of autologous BM-MSC was reported in Korea
2015 REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial protocol was reported in UK
Year Description
Year Description
Year Description
Year Description
Year Description

Pulmonary

Year Description
2008 Bone marrow mononuclear cells therapy was applied for chronic obstructive pulmonary disease/pulmonary emphysema and reported inhibiting or slowing effect on progression of disease in Brazil
2011 A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD was published in Brazil
2013 3 year follow up study was reported for patients with advanced chronic obstructive pulmonary disease in Brazil
Year Description
Year Description
2007 A preliminary study was reported that autologous EPCs seemed to be feasible and safe in patients with pulmonary arterial hypertension in China
2015 Delivery of endothelial progenitor cells over expressing endothelial nitric oxide synthase was applied in patients with Pulmonary Arterial Hypertension
Year Description
2013 Phase Ib, non-randomized trial of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis was published in Greece
2016 A study of safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis was reported
Year Description
Year Description
Year Description

Urology

Year Description
2007 Efficacy and safety of transferring autologous myoblasts and fibroblasts in the treatment of female SUI 1 year follow up study was published
2007 Two studies were retracted from the Lancet and World Journal of Urology for the ethical reasons
2008 Adult Stem Cell Therapy of Female Stress Urinary Incontinence was demonstrated for minimally invasive treatment modality
2008 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence was reported in Canada
2010 Human Cord Blood Stem Cell Therapy for Treatment of Stress Urinary Incontinence was repored in Korea
2011 2 Rumanian studies were reported
2011 The 4-year outcomes demonstrate that autologous myoblast transplantation for urinary incontinence in Iran
2013 A 2-Year Follow-Up of a Polish Investigation of autologous Muscle-Derived cells for the treatment of female Stress Urinary Incontinence was reported
Year Description
2016 The first study was reported for patients with Peyronie’s Disease using SVF in USA
Year Description
2010 A study on the effects of intracavernosal transplant of human umbilical cord blood stem cells on diabetic erectile dysfunction was reported in Korea
2016 Safety of Bone Marrow-Mononuclear Cells for erectile dysfunction was reported in France
Year Description
2015 Intradetrusor injection of adult muscle‐derived cells for the treatment of underactive bladder was published in USA
Year Description
Year Description
Year Description
Year Description
2008 [diabetes impotencies ] Human umbilical cord blood stem cells were used for the patients of diabetes impotencies

Eye

Year Description
Year Description
Year Description
Year Description
Year Description
Year Description
Year Description
Year Description

Etc

Year Description